Lantheus (LNTH) Upgraded to “Buy” at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a research note published on Wednesday.

Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Lantheus from a buy rating to a hold rating in a research report on Saturday, December 22nd. Zacks Investment Research raised shares of Lantheus from a hold rating to a buy rating and set a $19.00 price objective for the company in a research report on Tuesday, February 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $20.67.

Shares of Lantheus stock opened at $22.03 on Wednesday. The company has a market capitalization of $736.99 million, a P/E ratio of 23.44, a P/E/G ratio of 3.87 and a beta of 1.47. The company has a quick ratio of 2.87, a current ratio of 3.50 and a debt-to-equity ratio of 4.76. Lantheus has a 52 week low of $12.59 and a 52 week high of $22.50.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, February 19th. The medical equipment provider reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.09. The firm had revenue of $86.27 million during the quarter, compared to analyst estimates of $83.93 million. Lantheus had a net margin of 11.80% and a return on equity of 83.91%. Lantheus’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $2.47 EPS. Analysts expect that Lantheus will post 0.99 EPS for the current fiscal year.

In other Lantheus news, CEO Mary Anne Heino sold 9,564 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $16.47, for a total transaction of $157,519.08. Following the completion of the transaction, the chief executive officer now directly owns 630,782 shares of the company’s stock, valued at approximately $10,388,979.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Cesare Orlandi sold 4,057 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $18.06, for a total transaction of $73,269.42. Following the transaction, the insider now directly owns 73,689 shares of the company’s stock, valued at $1,330,823.34. The disclosure for this sale can be found here. Insiders have sold a total of 23,736 shares of company stock valued at $408,523 over the last three months. 1.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its position in Lantheus by 51.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 575 shares during the last quarter. Financial Gravity Companies Inc. purchased a new position in Lantheus during the 4th quarter worth approximately $45,000. Advisor Group Inc. raised its position in Lantheus by 1,837.2% during the 4th quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock worth $69,000 after buying an additional 4,152 shares during the last quarter. Gotham Asset Management LLC purchased a new position in Lantheus during the 4th quarter worth approximately $165,000. Finally, Municipal Employees Retirement System of Michigan purchased a new position in Lantheus during the 4th quarter worth approximately $171,000. 94.69% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Read More: Call Option

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.